Physician profile
Mark Vinson
NPI 1699255794
$681.33
in general payments reported to CMS, 2019-2025
15 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.50 · 2023: $99.33 · 2024: $180 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.83 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $123.12 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $88.01 | 2023-2025 | Rexulti, Jynarque |
| Lilly USA, LLC | $75.49 | 2024-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $71.10 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Viatris Specialty LLC | $68.30 | 2025 | Yupelri |
| Mylan Specialty L.P. | $40.86 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $37.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $36.02 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $30.63 | 2023-2024 | Gemtesa |
| Lundbeck LLC | $26.42 | 2025 | Rexulti |
| Dexcom, INC. | $24.06 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $21.48 | 2025 | |
| Glaxosmithkline, LLC. | $18.62 | 2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $13.06 | 2025 | Voquezna |
| Genentech USA, INC. | $6.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.